Opinion
Video
Jason Hafron, MD, considers the future for AI in urology
Author(s):
"I think AI is going to have a significant role. We're just at the tip of the iceberg," says Jason M. Hafron, MD, CMO.
Artificial intelligence (AI) has become a disruptor in nearly every sector, including health care. In a recent interview with Urology Times®, Jason M. Hafron, MD, CMO, speculated on the various ways in which AI will improve urologic care in the coming years, noting that we’re “just at the tip of the iceberg.”
He began by highlighting the recent commercialization of the first AI-based risk stratification tool, ArteraAI. According to Hafron, the test “looks [like] it will play a significant clinical role within the management of localized prostate cancer.”
ArteraAI is a multimodal artificial intelligence biomarker test that uses patients’ digital biopsy images and clinical data to help predict which patients may benefit from a particular therapy. The prognostic test has been validated in patients who have undergone active surveillance, radiation therapy, or had a radical prostatectomy.1
Hafron then discussed the opportunity for AI to alleviate some of the administrative burden placed on urologists, which is exacerbated by a high demand for urologic care. Specifically, he noted the potential to integrate AI via AI scribes or virtual AI nurses, which could bridge the gap in provider shortages.
However AI is integrated, Hafron believes it will continue to play a significant role in urologic care.
REFERENCE
1. Artera announces expansion of the ArteraAI Prostate Test to inform active surveillance decisions for lower risk prostate cancer patients. News release. Artera. August 6, 2024. Accessed April 2, 2025. https://www.businesswire.com/news/home/20240806340589/en/Artera-Announces-Expansion-of-the-ArteraAI-Prostate-Test-to-Inform-Active-Surveillance-Decisions-for-Lower-Risk-Prostate-Cancer-Patients
